Dominican Republic vs. Costa Rica: Manufacturing Comparison for US Companies

The Dominican Republic and Costa Rica are the two most comparable CAFTA-DR manufacturing destinations for US companies seeking high-quality, regulated-sector nearshore production. Both offer zero-tariff US access, established free zone ecosystems, FDA-familiar regulatory environments, and skilled bilingual workforces. The comparison between them defines the central nearshore manufacturing trade-off: Costa Rica’s depth and precision versus the Dominican Republic’s cost and scale.

For US companies selecting between these two markets, the decision turns on sector requirements, labor cost sensitivity, desired workforce technical depth, and the specific operational profile of the production being nearshored. This analysis provides a factual comparison across the dimensions that matter most.

Direct Comparison

Costa Rica: Precision and Technical Depth

Costa Rica’s manufacturing ecosystem — anchored by the Intel semiconductor operation established in 1997 and the subsequent wave of medical device and pharmaceutical investment it attracted — is optimized for precision engineering, technical complexity, and advanced manufacturing services. The country’s free zone workforce has accumulated deep skills in high-precision assembly, metrology, and advanced quality systems that are difficult to replicate quickly elsewhere. For US companies manufacturing Class III medical devices, advanced optical components, or semiconductor-related products, Costa Rica’s technical ecosystem provides capabilities that the DR is still building.

Dominican Republic: Cost, Scale, and Proximity

The Dominican Republic’s advantages over Costa Rica are most pronounced in: labor cost (30-50% lower fully loaded), labor pool depth (larger workforce for high-volume ramp-up), free zone infrastructure scale (more available space across more geographic corridors), and logistics — Port Caucedo’s 850,000+ TEU annual capacity versus Costa Rica’s Caldera port, with DR ocean transit to US East Coast 1-2 days faster. For high-volume medical packaging, pharmaceutical manufacturing, apparel, electronics assembly, and consumer goods, DR economics are stronger.

Sector-by-Sector Guidance

Related Resources

Caribbean Manufacturing Hub Investment Guide | Site Selection Framework | DR vs El Salvador & Guatemala | DR Labor Costs 2026

Frequently Asked Questions

Which country has stronger FDA inspection outcomes — DR or Costa Rica?

Both countries have established pharmaceutical and medical device manufacturers with successful FDA inspection records. Costa Rica’s longer history of complex medical device manufacturing provides a slightly larger sample of FDA inspection data. Dominican Republic manufacturers with established FDA inspection records — particularly in oral solid dosage pharmaceuticals and Class II medical devices — demonstrate comparable compliance performance. Neither country has a systematic FDA compliance disadvantage relative to the other.

Can a US company operate in both the DR and Costa Rica?

Yes, and several US medical device and pharmaceutical companies do. Multi-country CAFTA-DR platforms using DR for high-volume, cost-sensitive production and Costa Rica for precision, high-complexity work represent a sophisticated supply chain strategy that captures the best economics of both markets. The Caribbean Economic Corridor framework can accommodate Costa Rica as a complementary node alongside the DR anchor.

Explore More: EGS Insights Hub | DR Manufacturing Sectors | Contact Our Team